Cogene Ventures

Managing Directors Ryan Niddel and Naji Gehchan lead all investment decisions. Both founders are operators who have built and scaled healthcare companies, and the firm's investment committee draws directly on their domain expertise. The lean team structure means diligence is conducted by the principals themselves, often supplemented by clinicians and technologists within their LP network.

Cogene sources deal flow through its network of limited partners, many of whom are practicing physicians and health system executives. These LPs see clinical and operational gaps in real time and frequently refer founders whose solutions they have encountered in practice. The firm also sources from healthtech accelerators and academic medical centers in Houston, Boston, and San Francisco.

Cogene writes initial checks between $250,000 and $2 million, targeting seed and Series A rounds. The firm typically leads or co-leads rounds and reserves capital for follow-on investments. Its stage focus is early enough that many portfolio companies are pre-revenue or early-commercialization at the time of first investment.

Cogene has intentionally built a limited partner base of practicing physicians, hospital executives, and healthcare technologists rather than traditional institutional allocators. These LPs co-invest alongside the firm and contribute clinical validation, regulatory insight, and early-adopter access for portfolio companies. The structure functions more like a curated syndicate than a conventional venture fund.

Cogene typically takes a board observer or advisory board seat rather than a full board position in portfolio companies. The firm prefers to embed its principals and LP clinicians as hands-on resources for go-to-market and regulatory strategy without formal governance obligations that might limit its ability to support multiple companies simultaneously.

Cogene does not invest in therapeutics, biotech, or drug development, which require capital timelines and regulatory pathways outside the firm's expertise and fund structure. The firm also does not invest outside the United States. Its focus is exclusively on healthtech products that can reach the market through FDA 510(k) clearance, de novo classification, or software-as-a-medical-device pathways.

Cogene has not publicly disclosed a traditional fund structure, and its investment pattern is consistent with a deal-by-deal syndicate or rolling-fund model. Capital appears to be called on a per-deal basis from its LP network rather than from a committed blind pool, though the firm has not formally confirmed its fundraising structure.